Ampersand Biomedicines

Series-B
ampersand.bio Biotech & Healthcare Boston, United States Founded 2021 11–50 employees
Total Funding $65M
Latest Round $65M Series-B
Last Announced Mar 19, 2025
Investors 2 Backers
Decision Makers 6 Available

About Ampersand Biomedicines

Ampersand is enabling potent mechanisms to treat disease by creating and programming therapeutics that are more efficacious, without compromising on safety or tolerability.

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-B
Global Headquarters Boston, United States
Year Founded 2021
Team Size 11–50 employees
Tracked Since Nov 8, 2026

Web & Domain Identity

Official Website ampersand.bio
Domain Registered Date Undisclosed

Social & Network Presence

LinkedIn Corporate Company Profile

Company Milestones & Timeline

2 Events
  1. Capital Raise

    Raised $65,000,000 · Series-B

    fundraisingfox.com

  2. Milestone

    Company founded

    Boston, United States

Investors & Backers

2
Eli Lilly
Flagship Pioneering

Funding History

1 Round
Series-B equity · Mar 19, 2025

Founders & Leadership

4

Avak Kahvejian

Founder

Work email & phone locked Unlock →

Jason Gardner

CEO & Director

Work email & phone locked Unlock →

Noubar Afeyan

Founder

Work email & phone locked Unlock →

Raffi Afeyan

Founder

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

Recently funded startups
New SaaS launches
Never pay twice for contacts